Notch Signaling in Cancer: Mechanisms and Therapeutic Implications

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Notch Signaling in Cancer

Overview of Notch Pathway

Notch signaling is an evolutionarily conserved cell–cell communication mechanism that governs cell fate decisions, proliferation, differentiation, and apoptosis across metazoans. Unlike most signaling pathways that rely on second messengers or kinase cascades, Notch signaling is direct: ligand binding triggers a series of proteolytic cleavages that release the Notch intracellular domain (NICD), which then translocates to the nucleus to regulate gene transcription. This juxtacrine mode of signaling requires physical contact between neighboring cells, making it exquisitely sensitive to tissue architecture and cellular context.

In normal development, Notch signaling controls binary cell fate choices—such as whether a progenitor becomes a neuron or a glial cell, whether a T cell precursor commits to the αβ or γδ lineage, and whether intestinal stem cells maintain their stemness or differentiate into absorptive or secretory lineages. The pathway is also critical for boundary formation, lateral inhibition, and maintenance of stem cell pools in adult tissues. Given these broad roles, it is unsurprising that dysregulated Notch signaling contributes to a wide spectrum of human malignancies.

Historical Context in Cancer

The connection between Notch and cancer was first established in 1991, when a recurrent chromosomal translocation t(7;9)(q34;q34.3) was identified in a subset of T-cell acute lymphoblastic leukemia (T-ALL) patients. This translocation juxtaposed a truncated NOTCH1 gene to the T-cell receptor β locus, resulting in constitutive expression of a constitutively active, truncated Notch1 protein. This landmark finding established Notch as a bona fide oncogene in T-ALL.

For over a decade, the role of Notch in solid tumors remained ambiguous. However, subsequent studies revealed activating NOTCH1 mutations in approximately 10–15% of chronic lymphocytic leukemias, and pathway activation in breast, lung, pancreatic, and colorectal cancers. Conversely, loss-of-function mutations in NOTCH family members were identified in squamous cell carcinomas of the skin, head and neck, and esophagus, establishing Notch as a tumor suppressor in certain epithelial contexts. This dual nature—oncogene in some tissues, tumor suppressor in others—remains a central theme in understanding Notch biology in cancer.

The Notch Signaling Pathway: Core Components and Activation

Notch Receptors and Ligands

Mammals express four Notch receptors (Notch1–4) and five canonical ligands: three Delta-like ligands (DLL1, DLL3, DLL4) and two Jagged/Serrate ligands (JAG1, JAG2). The ligands are transmembrane proteins expressed on the surface of signal-sending cells, while the receptors are expressed on signal-receiving cells. Both receptors and ligands contain multiple epidermal growth factor (EGF)-like repeats in their extracellular domains, which mediate protein–protein interactions.

The Notch receptor is synthesized as a single polypeptide that undergoes cleavage by a furin-like convertase in the trans-Golgi network (S1 cleavage). This produces a heterodimeric receptor held together non-covalently at the cell surface: the extracellular domain (NECD) and the transmembrane/intracellular domain (NTMIC). The NECD contains 29–36 EGF-like repeats, with repeats 11–12 being critical for ligand binding. The NTMIC contains the transmembrane domain, a RAM domain, seven ankyrin (ANK) repeats, a transactivation domain (TAD), and a PEST domain that regulates protein stability.

Ligand–receptor interaction is governed by several factors: the specific EGF repeats engaged, the glycosylation state of the receptor, and the relative expression levels of ligands and receptors on opposing cells. Notably, DLL4 and JAG1 can have opposing effects on Notch signaling output, and the balance between them determines downstream transcriptional responses. For a more detailed treatment of ligand–receptor interactions, see the Notch Delta Signaling resource.

Proteolytic Cleavage and Nuclear Translocation

Upon ligand binding, the Notch receptor undergoes a conformational change that exposes the S2 cleavage site within the negative regulatory region (NRR). This site is cleaved by members of the A disintegrin and metalloprotease (ADAM) family, primarily ADAM10 and ADAM17 (also known as TACE). This S2 cleavage removes the NECD, leaving a membrane-tethered intermediate called the Notch extracellular truncation (NEXT) fragment.

The NEXT fragment is then a substrate for the γ-secretase complex, an intramembrane protease composed of presenilin 1 or 2 (PSEN1/PSEN2), nicastrin (NCSTN), anterior pharynx-defective 1 (APH1), and presenilin enhancer 2 (PEN2). γ-Secretase cleaves within the transmembrane domain at the S3 site, releasing the NICD into the cytoplasm. This is the rate-limiting step in Notch signaling and the primary target of pharmacological inhibition.

The entire process from ligand binding to NICD release occurs within minutes, and the signaling cascade is remarkably short—there are no amplification steps, no second messengers, and no kinase cascades. The NICD then translocates to the nucleus via a mechanism that involves the nuclear localization signals within the RAM and ANK domains, possibly assisted by importins.

Transcriptional Complex and Target Genes

In the nucleus, NICD forms a ternary complex with the DNA-binding protein CSL (CBF1/RBP-Jκ in mammals, Suppressor of Hairless in Drosophila, Lag-1 in C. elegans; hence the name CSL) and the co-activator Mastermind-like (MAML1–3). This complex binds to specific DNA sequences known as CSL-binding sites, which contain the core consensus sequence RTGRGAR (where R is purine, K is pyrimidine).

In the absence of NICD, CSL associates with co-repressors such as SMRT/NCoR, CIR1, and histone deacetylases (HDACs), maintaining target genes in a repressed state. Upon NICD binding, the co-repressor complex is displaced, and the NICD–CSL–MAML complex recruits additional co-activators including p300/CBP, which possess histone acetyltransferase activity. This chromatin remodeling leads to transcriptional activation.

The canonical Notch target genes include the basic helix-loop-helix (bHLH) transcription factors HES1, HES5, and HEY1, HEY2, and HEYL. These factors then regulate downstream effectors involved in cell cycle control, apoptosis, and differentiation. Additional direct targets include MYC, CCND1 (cyclin D1), CDK2, P21, and the Notch-regulated ankyrin repeat protein (NRARP). The specific set of target genes activated depends on cellular context, chromatin state, and the availability of cooperating transcription factors.

Mechanisms of Notch Dysregulation in Cancer

Activating Mutations and Copy Number Alterations

The most direct mechanism of Notch dysregulation in cancer is through activating mutations. In T-ALL, approximately 60% of cases harbor NOTCH1 mutations. These fall into two major classes: (1) mutations in the heterodimerization domain (HD) that destabilize the non-covalent interaction between NECD and NTMIC, leading to ligand-independent S2 cleavage; and (2) mutations in the PEST domain that remove degradation signals, prolonging NICD half-life. Some T-ALLs harbor mutations in both domains, producing a doubly activated receptor with both increased cleavage and decreased turnover.

In chronic lymphocytic leukemia (CLL), NOTCH1 mutations occur in approximately 10% of cases at diagnosis and up to 20% in relapsed disease. The most common mutation is a 2-base pair frameshift deletion (c.7544_7545delCT) in the PEST domain, which truncates the protein and removes the degradation motif. This mutation is associated with poor prognosis and increased risk of transformation to Richter syndrome.

Copy number alterations also contribute. Amplification of the NOTCH2 locus has been reported in B-cell lymphomas, and NOTCH3 amplification occurs in a subset of ovarian and breast cancers. Conversely, homozygous deletions of NOTCH1 are observed in some squamous cell carcinomas, consistent with its tumor suppressor role in these tissues.

Epigenetic Regulation

Epigenetic mechanisms modulate Notch pathway activity without altering the DNA sequence. DNA methylation of NOTCH gene promoters can silence expression; for example, hypermethylation of the NOTCH1 promoter has been reported in some lung cancers, correlating with reduced Notch1 protein levels. Conversely, hypomethylation of NOTCH2 and NOTCH3 promoters in gastric cancer leads to overexpression.

Histone modifications also play a role. The polycomb repressive complex 2 (PRC2) deposits H3K27me3 marks at Notch target gene promoters, maintaining them in a repressed state. In T-ALL, loss-of-function mutations in EZH2 (the catalytic subunit of PRC2) are mutually exclusive with NOTCH1 mutations, suggesting that both lesions converge on the same downstream transcriptional programs.

Non-coding RNAs add another layer of regulation. Several microRNAs (miRNAs) directly target Notch pathway components. For instance, miR-34a targets NOTCH1 and NOTCH2 mRNAs, and its expression is frequently lost in pancreatic cancer. Conversely, the long non-coding RNA LUNAR1 (leukemia-induced non-coding activator RNA) is upregulated by Notch signaling in T-ALL and enhances IGF1R expression, creating a positive feedback loop that promotes leukemic cell growth.

Crosstalk with Other Signaling Pathways

Notch signaling does not operate in isolation; extensive crosstalk with other pathways shapes its oncogenic output. The most well-characterized interaction is with the Wnt pathway. Both pathways converge on common target genes such as MYC and CCND1, and can synergize to promote proliferation. In intestinal crypts, Notch and Wnt Signaling in Cancer cooperate to maintain the stem cell compartment; inhibition of either pathway leads to loss of stemness and differentiation. Conversely, in some contexts, Notch can antagonize Wnt signaling by inducing expression of Wnt inhibitors such as DKK1.

The PI3K-AKT pathway is also intimately linked to Notch. Notch signaling upregulates PTEN expression in some contexts, while in others, Notch activates PI3K signaling through direct transcriptional upregulation of PIK3CA or through cross-talk with receptor tyrosine kinases. In T-ALL, PTEN loss is mutually exclusive with NOTCH1 mutations, suggesting that both lesions activate a common downstream survival pathway.

The NF-κB pathway is another important partner. Notch can activate NF-κB through direct interaction with IKKα/β or through transcriptional upregulation of NF-κB subunits. This crosstalk is particularly relevant in B-cell malignancies, where constitutive NF-κB activity is a hallmark of the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma.

Oncogenic and Tumor Suppressor Roles of Notch

Notch as an Oncogene

In hematological malignancies, Notch acts predominantly as an oncogene. In T-ALL, constitutively active Notch1 drives proliferation, blocks differentiation at the T-cell precursor stage, and promotes self-renewal. The oncogenic mechanism involves direct transcriptional activation of MYC, which in turn drives cell cycle progression and metabolic reprogramming. Notch also suppresses the tumor suppressor PTEN through the transcriptional repressor HES1, leading to activation of the PI3K-AKT pathway.

In breast cancer, Notch signaling is frequently upregulated, particularly in triple-negative and HER2-positive subtypes. Notch activation promotes cancer stem cell (CSC) self-renewal, epithelial-to-mesenchymal transition (EMT), and metastasis. High expression of JAG1 or DLL4 in tumor cells or in the tumor microenvironment correlates with poor prognosis. Notch also promotes resistance to conventional chemotherapy and radiotherapy by enhancing DNA damage repair and survival signaling.

In colorectal cancer, Notch signaling maintains the intestinal stem cell phenotype and cooperates with Wnt signaling to drive tumorigenesis. Inhibition of Notch in mouse models of intestinal adenomas leads to differentiation of tumor cells into goblet cells and reduced tumor burden. Similarly, in pancreatic cancer, Notch signaling is required for the maintenance of cancer stem cells and for the desmoplastic response that characterizes this malignancy.

Notch as a Tumor Suppressor

In contrast, Notch acts as a tumor suppressor in several epithelial tissues, most notably the skin, head and neck, esophagus, and bladder. Loss-of-function mutations in NOTCH1 and NOTCH2 are found in 30–70% of cutaneous squamous cell carcinomas (SCCs), head and neck SCCs, and esophageal SCCs. These mutations are predominantly inactivating—frameshifts, nonsense mutations, or missense mutations that disrupt receptor function.

The tumor suppressor mechanism is context-dependent. In keratinocytes, Notch signaling promotes differentiation and cell cycle arrest through upregulation of P21 and downregulation of MYC. Notch also induces expression of the tumor suppressor TP63 in some contexts, and loss of Notch leads to expansion of undifferentiated progenitor cells that are susceptible to transformation.

In small cell lung cancer (SCLC), NOTCH family genes are frequently inactivated, and reintroduction of active Notch in SCLC cell lines suppresses proliferation and induces neuroendocrine differentiation. This tumor suppressor role is mediated in part through suppression of the ASCL1 transcription factor, which is a lineage-specific oncogene in SCLC.

Context-Dependent Effects

The dual nature of Notch signaling is perhaps its most challenging aspect for therapeutic development. The same pathway that drives T-ALL can suppress skin cancer. This context-dependence arises from several factors:

1. Cell type and lineage: The transcriptional landscape of a cell determines which Notch target genes are accessible and functional.
2. Signal strength and duration: Low-level, transient Notch activation may promote differentiation, while high-level, sustained activation drives proliferation.
3. Cooperating mutations: The presence of mutations in other pathways (e.g., TP53, KRAS, PTEN) can convert Notch from a tumor suppressor to an oncogene.
4. Microenvironment: Ligand expression on stromal cells, hypoxia, and inflammatory signals all modulate Notch output.

This context-dependence is not unique to Notch—similar dual roles are observed in the Wnt Signaling Pathway and other developmental pathways—but it is particularly pronounced for Notch.

Notch Signaling in Specific Cancer Types

T-Cell Acute Lymphoblastic Leukemia

T-ALL is the paradigm for Notch-driven cancer. As noted, NOTCH1 mutations occur in ~60% of cases, and FBXW7 mutations (which stabilize NICD by preventing its ubiquitination) occur in an additional ~15%. The oncogenic program driven by Notch1 in T-ALL includes:

• Proliferation: Direct activation of MYC and CCND1
• Differentiation block: Suppression of E2A and E47 transcription factors that promote T-cell maturation
• Metabolism: Upregulation of glucose transporters and glycolytic enzymes
• Self-renewal: Maintenance of leukemic stem cells through activation of BMI1 and HES1

Therapeutic targeting of Notch in T-ALL with γ-secretase inhibitors (GSIs) has shown efficacy in preclinical models, but clinical trials have been limited by on-target gastrointestinal toxicity (secretory diarrhea) caused by inhibition of Notch signaling in intestinal goblet cells.

Breast Cancer

Notch signaling is activated in approximately 30–50% of breast cancers, with the highest frequency in triple-negative breast cancer (TNBC). Mechanisms of activation include:

• Overexpression of Notch receptors and ligands (JAG1, DLL4)
• Loss of negative regulators such as Numb (an endocytic adaptor that promotes Notch degradation)
• Hypoxia-induced upregulation of Notch ligands
• Crosstalk with estrogen receptor (ER) signaling in ER-positive tumors

In breast cancer, Notch promotes cancer stem cell self-renewal, EMT, and metastasis to bone and brain. High JAG1 expression in primary tumors correlates with increased risk of bone metastasis. Preclinical studies with GSIs and anti-DLL4 antibodies have shown promise, particularly in combination with chemotherapy.

Lung Cancer

Notch signaling has distinct roles in different lung cancer subtypes. In non-small cell lung cancer (NSCLC), Notch is frequently activated and promotes proliferation, EMT, and resistance to EGFR inhibitors. In contrast, in small cell lung cancer (SCLC), Notch acts as a tumor suppressor, and its loss promotes neuroendocrine differentiation and tumor growth.

The tumor suppressor role of Notch in SCLC is mediated through inhibition of ASCL1, a transcription factor that drives the neuroendocrine phenotype. Reintroduction of active Notch in SCLC cells induces a non-neuroendocrine phenotype and reduces tumorigenicity. This dichotomy within the same organ highlights the importance of cellular context in determining Notch function.

Other Malignancies

• Chronic lymphocytic leukemia (CLL): NOTCH1 PEST domain mutations in ~10–20% of cases; associated with poor prognosis and Richter transformation.
• Colorectal cancer: Notch activation maintains cancer stem cells; cooperates with Wnt signaling.
• Pancreatic cancer: Notch signaling is required for pancreatic cancer stem cell maintenance and desmoplasia.
• Glioblastoma: Notch promotes glioma stem cell self-renewal and angiogenesis through Vegf Notch Signaling crosstalk.
• Ovarian cancer: NOTCH3 amplification in ~20% of cases; associated with platinum resistance.
• Melanoma: Notch signaling promotes invasion and metastasis through upregulation of N-cadherin and MMPs.

Methods to Study Notch Signaling in Cancer

In Vitro Models

Cell lines remain the workhorse of Notch cancer research. Commonly used lines include Jurkat and MOLT-4 (T-ALL), MCF7 and MDA-MB-231 (breast cancer), and HCT116 (colorectal cancer). These lines can be manipulated using:

• Lentiviral/retroviral transduction: For overexpression of NICD, dominant-negative MAML1 (dnMAML1), or shRNA/miRNA against Notch components.
• CRISPR-Cas9: For gene knockout or knock-in of specific mutations (e.g., PEST domain deletions).
• Pharmacological inhibitors: GSIs (e.g., DAPT, compound E, dibenzazepine) at concentrations typically 1–10 μM for DAPT in cell culture.

Co-culture assays are used to study ligand-dependent signaling. In a typical assay, "signal-sending" cells expressing DLL1 or JAG1 are co-cultured with "signal-receiving" cells expressing the Notch receptor. Reporter cell lines carrying a CSL-responsive luciferase construct (e.g., 4xCSL-luc) are used to quantify pathway activity.

In Vivo Models

Genetically engineered mouse models (GEMMs) have been instrumental in defining Notch function in cancer. Key models include:

• VavP-Notch1-IC: Transgenic mice expressing NICD under the Vav promoter develop T-ALL.
• MMTV-NICD: Mammary gland-specific NICD expression drives breast tumorigenesis.
• K14-Cre;Notch1^fl/fl: Keratinocyte-specific Notch1 knockout leads to skin tumors.
• LSL-Kras^G12D;Pdx1-Cre;Notch2^fl/fl: Pancreatic cancer models with Notch2 deletion.

Patient-derived xenografts (PDXs) are increasingly used to test Notch-targeted therapies in a more clinically relevant context. PDX models retain the genetic heterogeneity and microenvironment of the original tumor, making them valuable for preclinical drug testing.

Molecular and Biochemical Assays

• Western blotting: Detection of NICD (cleaved Notch1) using antibodies specific to the V1744 cleavage site. A typical protocol involves lysing cells in RIPA buffer with protease inhibitors, separating 20–50 μg of protein on a 7.5% SDS-PAGE gel, and probing with anti-cleaved Notch1 (Val1744) antibody at 1:1000 dilution.
• Quantitative RT-PCR: Measurement of Notch target genes (HES1, HEY1, MYC) using SYBR Green or TaqMan assays. RNA is typically extracted using TRIzol, and cDNA is synthesized from 1 μg of RNA using random hexamers.
• Luciferase reporter assays: Cells are transfected with a CSL-luciferase reporter (e.g., pGL4.27-4xCSL-luc) and a Renilla luciferase control. After 24–48 hours, luciferase activity is measured using a dual-luciferase assay system.
• Immunohistochemistry (IHC): Detection of Notch1, Notch3, NICD, and downstream targets in tumor tissue sections. Antigen retrieval is typically performed in citrate buffer (pH 6.0) at 95°C for 20 minutes.

Genomic and Proteomic Approaches

• Whole-exome and whole-genome sequencing: Identification of NOTCH mutations in patient tumors.
• RNA-seq: Transcriptomic profiling to identify Notch-regulated gene signatures.
• ChIP-seq: Genome-wide mapping of NICD/CSL binding sites. A typical protocol involves crosslinking cells with 1% formaldehyde for 10 minutes at room temperature, sonicating chromatin to 200–500 bp fragments, and immunoprecipitating with anti-NICD or anti-CSL antibodies.
• Mass spectrometry: Identification of NICD-interacting proteins and post-translational modifications.

Therapeutic Targeting of Notch Signaling

Gamma-Secretase Inhibitors

GSIs are the most extensively studied class of Notch inhibitors. These small molecules block the γ-secretase complex, preventing S3 cleavage and NICD release. Examples include:

• DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester): A dipeptide-based GSI used primarily in preclinical studies.
• MK-0752: An oral GSI that has been evaluated in phase I/II clinical trials for T-ALL, breast cancer, and glioblastoma.
• RO4929097: A GSI tested in phase II trials for metastatic colorectal cancer and recurrent glioblastoma.
• LY3039478 (crenigacestat): A potent GSI with improved selectivity, currently in clinical trials for multiple solid tumors.

The major limitation of GSIs is on-target gastrointestinal toxicity. Because Notch signaling is required for intestinal goblet cell differentiation, GSI treatment causes secretory diarrhea and intestinal metaplasia. This toxicity has limited the maximum tolerated dose and, consequently, the efficacy of GSIs as monotherapies.

Antibody-Based Therapies

To achieve greater selectivity, antibody-based approaches targeting specific Notch receptors or ligands have been developed:

• Anti-Notch1 antibodies (e.g., brontictuzumab): Block Notch1 activation by binding to the NRR and preventing S2 cleavage. These spare Notch2/3/4 signaling, reducing gastrointestinal toxicity.
• Anti-Notch2/3 antibodies: Less well-developed but potentially useful for cancers driven by these receptors.
• Anti-DLL4 antibodies (e.g., demcizumab): Block DLL4-mediated Notch signaling. DLL4 inhibition also has anti-angiogenic effects, as DLL4-Notch signaling regulates vascular sprouting. However, chronic DLL4 blockade causes vascular neoplasms in preclinical models, raising safety concerns.
• Anti-JAG1 antibodies: In early development; JAG1 is overexpressed in several cancers and contributes to Notch activation in the tumor microenvironment.

Combination Therapies

Given the context-dependent roles of Notch and the toxicity of pan-Notch inhibition, combination strategies are being explored:

• GSI + chemotherapy: In TNBC, GSI combined with docetaxel has shown additive effects in preclinical models.
• GSI + anti-angiogenic therapy: Combining DLL4 blockade with VEGF inhibitors (e.g., bevacizumab) may produce more effective anti-angiogenic responses.
• GSI + PI3K inhibitors: In T-ALL, combined inhibition of Notch and PI3K/AKT/mTOR pathways overcomes resistance and reduces toxicity.
• GSI + immunotherapy: Notch signaling in T cells regulates effector function and exhaustion; combining Notch inhibitors with checkpoint blockade (anti-PD-1/PD-L1) is an active area of investigation.

Resistance Mechanisms

Resistance to Notch-targeted therapies arises through several mechanisms:

1. Compensatory upregulation of other Notch receptors: Inhibition of Notch1 may lead to increased Notch2/3 signaling.
2. Activation of bypass pathways: PI3K-AKT, MAPK, and Wnt signaling can compensate for Notch inhibition.
3. Mutations in downstream effectors: Mutations in FBXW7 stabilize NICD even in the presence of GSIs.
4. Tumor microenvironment: Stromal cells may provide ligands that activate Notch signaling in tumor cells, and this paracrine signaling may be less sensitive to GSI inhibition.
5. Cancer stem cell plasticity: Notch inhibition may select for CSC populations that are less dependent on Notch signaling.

Common Pitfalls and Misconceptions in Studying Notch Signaling

Oversimplifying the Pathway

A frequent error is treating Notch signaling as a linear, uniform pathway. In reality, there are four receptors, five ligands, and multiple downstream effectors, each with distinct expression patterns and functions. Notch1 and Notch3 can have opposing effects in the same tumor type. Similarly, DLL4 and JAG1 often elicit different outcomes—DLL4 tends to promote stem cell maintenance, while JAG1 can drive differentiation or EMT depending on context.

Another oversimplification is assuming that all Notch signaling is ligand-dependent. Ligand-independent activation occurs through mutations in the NRR or PEST domain, and through aberrant cleavage by other proteases. Additionally, Notch can signal through non-canonical pathways that do not involve CSL, such as through interaction with β-catenin or NF-κB.

Ignoring Cellular Context

Notch signaling output is profoundly influenced by cellular context. The same NICD that drives T-ALL can suppress skin cancer. This context-dependence means that results from one cell type cannot be extrapolated to another. Students often make the mistake of assuming that a Notch inhibitor that works in one cancer will work in all cancers, or that Notch activation is always oncogenic.

Context also matters at the level of signal strength and duration. Transient Notch activation during development can specify a cell fate, while sustained activation in cancer drives proliferation. Experimental systems that use constitutive NICD overexpression may not recapitulate the dynamics of endogenous Notch signaling.

Misinterpreting Experimental Data

Several technical pitfalls lead to misinterpretation:

1. Using total Notch antibodies instead of cleaved NICD antibodies: Total Notch1 levels do not reflect pathway activity. Only the cleaved NICD (detected with anti-cleaved Notch1 Val1744) indicates active signaling.
2. Measuring target gene expression without verifying CSL-dependence: Not all HES1 expression is Notch-dependent; HES1 can be regulated by other pathways (e.g., SHH, WNT).
3. Using GSI concentrations that are too high: High GSI concentrations can have off-target effects, including inhibition of other intramembrane proteases. The typical IC50 for DAPT on γ-secretase is ~20 nM, but concentrations above 10 μM can cause non-specific cytotoxicity.
4. Ignoring ligand-independent signaling: In cells with NRR mutations, GSIs may be ineffective because the receptor is already cleaved at S2.
5. Failing to account for Notch in the tumor microenvironment: Notch signaling in stromal cells, endothelial cells, and immune cells can influence tumor growth independently of tumor cell-intrinsic Notch.

Summary and Future Directions

Key Takeaways

• Notch signaling is a direct cell–cell communication pathway that regulates cell fate decisions, proliferation, and differentiation.
• Dysregulation of Notch signaling contributes to cancer through activating mutations, epigenetic changes, and crosstalk with other pathways.
• Notch acts as an oncogene in T-ALL, breast cancer, and colorectal cancer, but as a tumor suppressor in squamous cell carcinomas and SCLC.
• The context-dependent dual role of Notch complicates therapeutic targeting.
• GSIs are the most studied Notch inhibitors but cause gastrointestinal toxicity; antibody-based approaches offer greater selectivity.
• Resistance to Notch-targeted therapies arises through multiple mechanisms, including bypass pathway activation and tumor microenvironment effects.

Unanswered Questions

Several fundamental questions remain:

1. How is the context-dependence of Notch signaling determined at the molecular level? What chromatin marks, transcription factor combinations, and enhancer elements dictate whether Notch activates oncogenic or tumor suppressor programs?
2. What is the role of non-canonical Notch signaling in cancer? CSL-independent Notch signaling is poorly understood but may contribute to therapy resistance.
3. How can we predict which patients will respond to Notch-targeted therapies? Biomarkers of Notch pathway activation are needed to guide patient selection.
4. What is the optimal way to combine Notch inhibitors with other therapies? The sequence and timing of combination treatments may be critical for efficacy and toxicity.

Emerging Research Areas

• Notch in the tumor immune microenvironment: Notch signaling regulates T cell differentiation, exhaustion, and anti-tumor immunity. Modulating Notch in immune cells may enhance checkpoint blockade efficacy.
• Notch and cancer metabolism: Notch signaling rewires cellular metabolism, including glucose uptake, glutamine metabolism, and lipid synthesis. Targeting these metabolic dependencies may be a novel therapeutic approach.
• Notch in therapy resistance: Notch signaling is implicated in resistance to chemotherapy, radiotherapy, and targeted therapies. Understanding these mechanisms may lead to strategies to overcome resistance.
• Notch in organoid models: Patient-derived organoids recapitulate Notch signaling in a physiologically relevant 3D context and are being used for drug screening and mechanistic studies.
• Proteolysis-targeting chimeras (PROTACs): These agents degrade Notch receptors or components of the γ-secretase complex, potentially overcoming the limitations of enzymatic inhibitors.

The Notch field continues to evolve, and the lessons learned from studying this pathway in cancer have illuminated fundamental principles of developmental biology, cell fate determination, and tissue homeostasis. As our understanding of the context-dependent roles of Notch deepens, so too will our ability to harness this pathway for therapeutic benefit.

Frequently Asked Questions

What is Notch signaling and how does it cause cancer?

Notch signaling is a direct cell–cell communication pathway in which a membrane-bound ligand on one cell activates a Notch receptor on a neighboring cell. This triggers proteolytic cleavage that releases the Notch intracellular domain (NICD), which enters the nucleus and regulates gene transcription. In cancer, aberrant Notch activation can drive proliferation, block differentiation, promote cancer stem cell self-renewal, and enhance metastasis. Conversely, in some tissues, loss of Notch signaling removes a differentiation checkpoint, also leading to cancer.

Is Notch signaling always oncogenic?

No. Notch signaling has dual roles in cancer. It acts as an oncogene in T-ALL, breast cancer, colorectal cancer, and several other malignancies. However, it functions as a tumor suppressor in squamous cell carcinomas of the skin, head and neck, and esophagus, as well as in small cell lung cancer. The outcome depends on cellular context, including the cell type, the presence of cooperating mutations, and the tumor microenvironment.

What are the main components of the Notch pathway?

The main components are: four Notch receptors (Notch1–4), five canonical ligands (DLL1, DLL3, DLL4, JAG1, JAG2), the proteases that cleave the receptor (ADAM10/17 and the γ-secretase complex), the nuclear DNA-binding protein CSL (RBP-Jκ), the co-activator Mastermind-like (MAML1–3), and downstream target genes such as HES1, HEY1, and MYC.

How is Notch signaling studied in cancer research?

Notch signaling is studied using cell lines with genetic manipulation (CRISPR, shRNA, overexpression), pharmacological inhibitors (GSIs like DAPT), reporter assays (CSL-luciferase), Western blotting for cleaved NICD, quantitative RT-PCR for target genes, and in vivo models including genetically engineered mice and patient-derived xenografts. High-throughput approaches include RNA-seq, ChIP-seq, and whole-exome sequencing.

What are gamma-secretase inhibitors and how do they work?

Gamma-secretase inhibitors (GSIs) are small molecules that block the γ-secretase complex, an intramembrane protease that cleaves the Notch receptor at the S3 site. This cleavage is required for release of NICD and activation of Notch signaling. By inhibiting γ-secretase, GSIs prevent Notch signaling. However, because γ-secretase cleaves many substrates beyond Notch (including amyloid precursor protein, CD44, and ErbB4), GSIs have broad effects and cause on-target gastrointestinal toxicity.

Why is Notch signaling difficult to target therapeutically?

Notch signaling is difficult to target because: (1) it has dual oncogenic and tumor suppressor roles, so systemic inhibition may promote cancer in some tissues while treating it in others; (2) pan-Notch inhibition causes gastrointestinal toxicity; (3) there are four receptors and five ligands with overlapping but distinct functions, making selective targeting challenging; (4) resistance develops through compensatory upregulation of other receptors or activation of bypass pathways; and (5) Notch signaling in the tumor microenvironment complicates the therapeutic response.

What are common mistakes when learning about Notch signaling?

Common mistakes include: (1) treating Notch as a linear pathway when it has multiple receptors, ligands, and context-dependent outputs; (2) assuming Notch is always oncogenic; (3) using total Notch antibodies instead of cleaved NICD antibodies to assess pathway activity; (4) ignoring ligand-independent Notch activation; (5) overlooking the role of Notch in non-tumor cells; and (6) extrapolating results from one cancer type to another without considering cellular context.

Key Takeaways

• Notch signaling is a direct, juxtacrine cell–cell communication pathway that regulates cell fate decisions, proliferation, and differentiation through proteolytic release of NICD and transcriptional regulation via the CSL–MAML complex.
• Notch dysregulation in cancer occurs through activating mutations (T-ALL, CLL), copy number alterations, epigenetic silencing or activation, and extensive crosstalk with Wnt, PI3K-AKT, and NF-κB pathways.
• Notch has dual roles in cancer: it is oncogenic in T-ALL, breast, colorectal, and pancreatic cancers, but tumor suppressive in squamous cell carcinomas and SCLC; this context-dependence is the central challenge for therapeutic development.
• GSIs block Notch signaling by inhibiting the γ-secretase complex but cause dose-limiting gastrointestinal toxicity; antibody-based therapies targeting specific receptors or ligands offer improved selectivity.
• Resistance to Notch-targeted therapies arises through compensatory receptor upregulation, bypass pathway activation, FBXW7 mutations, and tumor microenvironment effects.
• Studying Notch requires careful experimental design, including use of cleaved NICD-specific antibodies, appropriate GSI concentrations, and consideration of cellular context and ligand-independent signaling.
• Future directions include targeting Notch in the tumor immune microenvironment, understanding Notch-regulated metabolism, and developing PROTACs for selective Notch degradation.

Further Reading

• Miele L, Golde T, Osborne B. Notch signaling in cancer. Current molecular medicine. 2006. PubMed 17168741
• Li S et al. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities. Cell communication and signaling : CCS. 2023. PubMed 37770930
• Li X et al. The Notch signaling pathway: a potential target for cancer immunotherapy. Journal of hematology & oncology. 2023. PubMed 37131214
• Allenspach EJ et al. Notch signaling in cancer. Cancer biology & therapy. 2002. PubMed 12496471
• Koch U, Radtke F. Notch signaling in solid tumors. Current topics in developmental biology. 2010. PubMed 2081640392013-9)
• Pagliaro L, Sorrentino C, Roti G. Targeting Notch Trafficking and Processing in Cancers. Cells. 2020. PubMed 33003595

Related Clinical & Scientific Guides

• MAPK Pathway: Mechanism, Function, and Clinical Relevance
• Mammalian Cell Culture Bioreactors: A Practical Guide
• Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks